FINISHED DOSAGE FORMULATIONS
ISONIAZID; PYRAZINAMIDE; RIFAMPIN
Drug : RIFATER
Dosage Form : TABLET; ORAL
Application Number : 50705
Country : US
Patented : No
Drug : QUINAPRIL HYDROCHLORIDE
Dosage Form : TABLET; ORAL
Application Number : 75504
Country : US
Patented : No
Drug : ESOMEPRAZOLE MAGNESIUM
Dosage Form : CAPSULE, DELAYED REL PELLETS; ORAL
Application Number : 205606
Country : US
Patented : No
Drug : QUINAPRIL HYDROCHLORIDE
Dosage Form : TABLET; ORAL
Application Number : 202725
Country : US
Patented : No
Drug : LAMOTRIGINE
Dosage Form : TABLET, FOR SUSPENSION; ORAL
Application Number : 90401
Country : US
Patented : No
Drug : LAMOTRIGINE
Dosage Form : TABLET; ORAL
Application Number : 90401
Country : US
Patented : No
Drug : ESOMEPRAZOLE MAGNESIUM
Dosage Form : CAPSULE, DELAYED RELEASE; ORAL
Application Number : 209339
Country : US
Patented : No
Drug : LANSOPRAZOLE
Dosage Form : CAPSULE, DELAYED REL PELLETS; ORAL
Application Number : 207156
Country : US
Patented : No
Drug : LANSOPRAZOLE
Dosage Form : CAPSULE, DELAYED REL PELLETS; ORAL
Application Number : 202727
Country : US
Patented : No
Drug : LANSOPRAZOLE
Dosage Form : CAPSULE, DELAYED REL PELLETS; ORAL
Application Number : 205868
Country : US
Patented : No
EXCIPIENTS BY APPLICATIONS
Application : Co-Processed Excipients
Excipient Details : AHMC 0600 is a co-processed aluminum hydroxide and magnesium carbonate powder used in immediate-relief antacid tablet formulation.
Pharmacopoeia Ref : NA
Technical Specs : Apparent Density: 0.30-0.40 (g/mL)
Ingredient(s) : Magnesium Carbonate Excipient
Application : Co-Processed Excipients
Excipient Details : AHMC 0611 is a co-processed aluminum hydroxide & magnesium carbonate micronized powder used in immediate-relief antacid tablets & liquid suspensions.
Pharmacopoeia Ref : NA
Technical Specs : Tapped NMT: 0.2
Ingredient(s) : Magnesium Carbonate Excipient
MARKET PLACE
Reply
25 May 2022